Robert Wasserman
Stock Analyst at Benchmark
(3.34)
# 1,058
Out of 5,105 analysts
111
Total ratings
49.53%
Success rate
2.98%
Average return
Main Sectors:
Stocks Rated by Robert Wasserman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRLB Proto Labs | Maintains: Buy | $45 → $55 | $52.57 | +4.62% | 7 | Nov 3, 2025 | |
| ITGR Integer Holdings | Downgrades: Hold | n/a | $72.72 | - | 12 | Oct 24, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Buy | $75 → $90 | $62.21 | +44.67% | 10 | Sep 24, 2025 | |
| INTS Intensity Therapeutics | Maintains: Speculative Buy | $4 → $1.5 | $0.47 | +219.15% | 7 | Aug 20, 2025 | |
| TECH Bio-Techne | Reiterates: Buy | $75 | $58.51 | +28.18% | 7 | Jun 5, 2025 | |
| KMDA Kamada | Reiterates: Buy | $15 | $7.02 | +113.68% | 2 | May 15, 2025 | |
| OABI OmniAb | Reiterates: Buy | $6 | $2.15 | +179.07% | 9 | May 12, 2025 | |
| XOMA XOMA Royalty | Initiates: Buy | $35 | $25.22 | +38.78% | 1 | Apr 17, 2025 | |
| ABCL AbCellera Biologics | Reiterates: Hold | n/a | $3.62 | - | 6 | Mar 3, 2025 | |
| BLFS BioLife Solutions | Reiterates: Buy | $30 | $24.39 | +23.00% | 6 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $8 | $2.29 | +249.34% | 6 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $5 | $5.02 | -0.40% | 3 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $12 | $11.41 | +5.17% | 17 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $1.67 | - | 7 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $157.39 | - | 3 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $3.29 | +21.58% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $0.27 | +1,381.48% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $75 | $2.93 | +2,459.73% | 2 | Apr 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $226.33 | - | 3 | Oct 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $580 | $572.28 | +1.35% | 1 | Jul 16, 2021 |
Proto Labs
Nov 3, 2025
Maintains: Buy
Price Target: $45 → $55
Current: $52.57
Upside: +4.62%
Integer Holdings
Oct 24, 2025
Downgrades: Hold
Price Target: n/a
Current: $72.72
Upside: -
Halozyme Therapeutics
Sep 24, 2025
Maintains: Buy
Price Target: $75 → $90
Current: $62.21
Upside: +44.67%
Intensity Therapeutics
Aug 20, 2025
Maintains: Speculative Buy
Price Target: $4 → $1.5
Current: $0.47
Upside: +219.15%
Bio-Techne
Jun 5, 2025
Reiterates: Buy
Price Target: $75
Current: $58.51
Upside: +28.18%
Kamada
May 15, 2025
Reiterates: Buy
Price Target: $15
Current: $7.02
Upside: +113.68%
OmniAb
May 12, 2025
Reiterates: Buy
Price Target: $6
Current: $2.15
Upside: +179.07%
XOMA Royalty
Apr 17, 2025
Initiates: Buy
Price Target: $35
Current: $25.22
Upside: +38.78%
AbCellera Biologics
Mar 3, 2025
Reiterates: Hold
Price Target: n/a
Current: $3.62
Upside: -
BioLife Solutions
Dec 19, 2024
Reiterates: Buy
Price Target: $30
Current: $24.39
Upside: +23.00%
Nov 19, 2024
Reiterates: Speculative Buy
Price Target: $8
Current: $2.29
Upside: +249.34%
Nov 12, 2024
Reiterates: Speculative Buy
Price Target: $5
Current: $5.02
Upside: -0.40%
Nov 7, 2024
Maintains: Buy
Price Target: $8 → $12
Current: $11.41
Upside: +5.17%
Nov 4, 2024
Reiterates: Hold
Price Target: n/a
Current: $1.67
Upside: -
Aug 5, 2024
Reiterates: Hold
Price Target: n/a
Current: $157.39
Upside: -
Mar 7, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $3.29
Upside: +21.58%
Mar 6, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $0.27
Upside: +1,381.48%
Apr 6, 2023
Reiterates: Speculative Buy
Price Target: $75
Current: $2.93
Upside: +2,459.73%
Oct 24, 2022
Downgrades: Hold
Price Target: n/a
Current: $226.33
Upside: -
Jul 16, 2021
Initiates: Buy
Price Target: $580
Current: $572.28
Upside: +1.35%